Format

Send to

Choose Destination
Int J Tuberc Lung Dis. 2012 Feb;16(2):206-8. doi: 10.5588/ijtld.11.0395.

False-positive rifampicin resistance on Xpert® MTB/RIF: case report and clinical implications.

Author information

1
Department of Epidemiology, University of North Carolina, Chapel Hill, North Carolina 27599, USA. vanrie@email.unc.edu

Abstract

The World Health Organization had endorsed Xpert® MTB/RIF (Xpert) as the initial diagnostic for multidrug-resistant tuberculosis (TB) or TB suspects co-infected with the human immunodeficiency virus. We investigated an unexpected case of rifampicin (RMP) resistance on Xpert using repeat Xpert, smear microscopy, MTBDRplus assay, culture, drug susceptibility testing, spoligotyping and rpoB gene sequencing. A false-positive result was most likely, given the wild type rpoB gene sequence and exclusion of both mixed infection and mixture of drug-susceptible and drug-resistant populations. When decentralising Xpert, test performance characteristics need to be understood by health care workers and methods of confirmation of RMP resistance need to be accessible.

PMID:
22236921
PMCID:
PMC3680645
DOI:
10.5588/ijtld.11.0395
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Ingenta plc Icon for PubMed Central
Loading ...
Support Center